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Intranasal vaccinationTH2-biased immune responses are associated with inadequate protection against some pathogens and
with cancer, colitis, asthma and allergy. Since most currently used vaccine adjuvants induce a
TH2-biased response, this has led to interest in developing adjuvants capable of activating TH1 immunity
and modulating existing TH2 responses. Immunotherapies to shift immune responses from TH2 to TH1
have generally required prolonged immunization protocols and have not induced effective TH1 responses.
We have demonstrated that nanoscale emulsions (NE), a novel mucosal adjuvant, induce robust IgA and
IgG antibody responses and TH1/TH17 cellular immunity resulting in protection against a variety of res-
piratory and mucosal infections. Because intranasal (i.n.) delivery of NE adjuvant consistently induces
TH1/TH17 biased responses, we hypothesized that NE could be used as a therapeutic vaccine to redirect
existing TH2 polarized immunity towards a more balanced TH1/TH2 profile. To test this, a TH2 immune
response was established by intramuscular immunization of mice with alum-adjuvanted hepatitis B sur-
face antigen (HBs), followed by a single subsequent i.n. immunization with NE-HBs. These animals exhib-
ited increased TH1 associated immune responses and IL-17, and decreased TH2 cytokines (IL-4 and IL-5)
and IgG1. NE immunization induced regulatory T cells and IL-10, and IL-10 was required for the suppres-
sion of TH2 immunity. These data demonstrate that NE-based vaccines can modulate existing TH2
immune responses to promote TH1/TH17 immunity and suggest the potential therapeutic use of NE
vaccines for diseases associated with TH2 immunity.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
CD4+ effector T cell responses are classified according to their
cytokine and transcription factor profiles, with TH1 and TH2 cells
being the most widely studied types [1]. Differentiation of TH1 cells
is driven by IL-12 secreted bymacrophages and IFN-c from T cells or
NK cells, and results in the production of TH1-type cytokines includ-ing IFN-c, IL-2 and TNF-a. In mice, IFN-c enhances immunoglobulin
class switching to increase production of IgG2a and IgG2b sub-
classes as well as activation of other TH1 cell-mediated effector
responses [2]. Alternatively, TH2 responses can be initiated by IL-
4-dependent differentiation of TH2 effector CD4+ cells that produce
TH2-type cytokines, including IL-4, IL-5, IL-9 and IL-13, which can
culminate in the increased production of IgG1 subclass and IgE anti-
bodies. The TH1/TH2 paradigm is useful for classification of immune
responses and becomes better defined as mechanisms of action of
CD4+ effector T cells are further elucidated.
The type of cell-mediated immunity affects the induction
of specific protective immunity to infectious diseases, inflamma-
tory responses, allergy or autoimmunity and even can increase
susceptibility to certain infections [3,4]. This is of particular
importance in vaccine development because adjuvants are able
to skew helper T cell profiles, and choosing the appropriate adju-
vant may influence efficacy [5]. The most widely used adjuvant
alum induces strong TH2-associated immune responses which are
less effective against pathogens for which TH1 cell-mediated
immunity is required for clearance [6–8]. Because of this, a number
Fig. 1. Design and schedule of immunomodulation studies.
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liposomes, CpG-containing oligodinucleotides, monophosphoryl
lipid A, and QS-21 are being evaluated both in animal studies
and in clinical trials [9–12]. Many of these adjuvants are under
development for production of vaccines that may be used in people
who have already been exposed to the same antigen or pathogen,
either through prior vaccination or infection. In the case of individ-
uals previously primed to have a TH2 skewed immune response
from an alum-adjuvanted vaccine, it is unclear if boosting with a
TH1-polarizing vaccine adjuvant would redirect the immune
response towards a TH1 response, or if it would simply boost the
TH2 responses for which the immune system had already been
primed. Additionally, a considerable interest has been directed
towards development of strategies for modulation of existing TH2
immune responses, especially for the alleviation of TH2-biased
allergic responses [13,14]. Adjuvants capable of redirecting
established antigen-specific TH2 responses to induce TH1 while
suppressing TH2 immunity have the potential for impacting a
variety of diseases driven by aberrant TH2 immune responses.
Our group has developed a nanoscale oil-in-water emulsion
(nanoemulsion, NE) vaccine adjuvant platform that when delivered
intranasally (i.n.) induces robust systemic and mucosal responses
without local inflammatory effects [15–20]. In animal studies, i.n.
immunizations with NE mixed with a variety of viral and
bacteria-derived antigens, including influenza, hepatitis B, respira-
tory syncytial virus, vaccinia and anthrax, yields high protective
antibody titers. In contrast to adjuvants like alum that induce
TH2-biased immune responses [6,21,22], nasally administered NE
vaccines result in TH1 and TH17 polarized immune responses
[18,23,24]. Regardless of the model tested, TH2 cytokine responses
in animals immunized with NE are always low, and no significant
production of IgE has been observed. This is true even in BALB/c
mice that are inherently biased towards a TH2-type response
[25]. Because this NE adjuvant is a robust TH1-polarizing adjuvant,
we hypothesized that it would be a good candidate for redirecting
established TH2 immune responses to a more balanced TH1/TH2/
TH17. In proof-of-concept studies presented here, we have investi-
gated the effect of nasal administration of a NE vaccine in mice pre-
viously vaccinated with an alum-adjuvanted vaccine.
2. Material and methods
2.1. Antigen and adjuvants
The recombinant hepatitis B surface antigen (HBs) was supplied
by Human Biologicals Institute (Indian Immunologics, Ltd, Hyder-
abad, India). The endotoxin level was determined to be <7.5
EU/20 lg of HBs, which is significantly below the internationally
accepted standard of 630 EU/20 lg of protein. Ovalbumin (ova)
was purchased from Sigma–Aldrich. Ova peptides, class
I-restricted ova 257–264 (SIINFEKL, ova I) and class II-restricted
ova 323–339 (ova II) were purchased from Invitrogen. Nanoemul-
sion adjuvant (NE) was supplied by NanoBio Corporation, Ann
Arbor, MI. NE was produced by a high speed emulsification of ultra
pure soybean oil with cetyl pyridinium chloride, Tween 80
and ethanol in water, with resultant NE droplets with average
350–400 nm diameter [18]. Aluminum hydroxide (alum) was
purchased from Sigma–Aldrich, Inc. All reagents were tested for
the presence of endotoxin using RAW-Blue cell-based assay
in vitro (InvivoGen, San Diego, CA).
2.2. Mice and immunizations
Pathogen-free CD-1 mice (females 6–8 weeks old) were pur-
chased from the Charles River Laboratories. All animal procedures
were performed according to the University Committee on the Useand Care of Animals at the University of Michigan. Immunization
schedule is shown in Fig. 1. For all immunizations, mice were anes-
thetized under isoflurane anesthesia using the IMPAC6 precision
vaporizer. Intranasal (i.n.) immunizations were done using a pip-
ette tip by administration of 5 ll/nare of formulation containing
20 lg of antigen mixed with 20% NE. Antigen mixed with PBS alone
served as a control. Intramuscular immunizations (i.m.) were per-
formed by injection of 50 ll containing 20 lg of antigen adsorbed
on 0.5 mg/ml alum into the epaxial muscle as described previously
[18]. Sera were obtained by saphenous vein bleeding, and spleno-
cytes were harvested at the end of the experiment. In IL-10 deple-
tion experiments, mice were injected i.p. with 1 mg anti-IL-10
(purified from rabbit serum [26]) or control rabbit IgG 12 h before
and 2 days after NE immunization.
2.3. Measurement of serum IgG subclasses
Serum antibody and IgG subclasses titers were determined by
ELISA, with plates coated with 5 lg/ml of HBs as described previ-
ously [18].
2.4. Analysis of cytokine expression
Single cell suspensions of freshly isolated mouse splenocytes
were cultured at 4  106 cells/ml with or without antigen
(10 lg/ml). After 48 h, supernatants were collected and analyzed
for the presence of cytokines using Milliplex Mouse Cytokine/
Chemokine Immunoassay Kit (Millipore, Billerica, MA).
2.5. Measurement of the induction of regulatory T cells (Tregs) after NE
immunization
Mice were immunized i.n. with ova and NE (ova-NE) or
non-adjuvated ova (ova-PBS) at weeks 0 and 4. Splenocytes were
harvested at 1 and 7 weeks after the first immunization. Red blood
cell depleted single cell suspensions were stained by flow cytome-
try to quantify regulatory T cells. Fc receptors were blocked with
purified anti-CD16/32 (clone 93, BioLegend) and surface markers
were stained using antibodies against CD3 (145-2C11), CD4
(RM4-5) and CD25 (7D4) (all from eBioscience or BD Biosciences),
permeabilized, fixed and labeled for intracellular Foxp3 (FJK-16s).
Samples were acquired on an Accuri C6 flow cytometer (BD
Biosciences). Data were analyzed using FlowJo (Treestar).
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Results are presented as the geometric mean ± 95% confidence
interval. Statistical comparisons were assessed by the Mann–Whit-
ney test using GraphPad Prism version 6 (GraphPad Software). The
p value < 0.05 was considered as significant. In every reported
result the data shown are representative of at least 2 experiments.
3. Results
3.1. Mucosal immunization with NE adjuvant modifies TH2 polarized
immune response
To elicit the TH2 response, mice were immunized with two i.m.
injections of 20 lg HBs adsorbed on alum [21]. Analysis of serum
IgG subclass and cytokine expression confirmed that HBs-alumFig. 2. Modulation of TH2 immunity with NE adjuvant. Mice were immunized i.m. with H
NE. (A) Serum HBs-specific antibody subclass titers determined at week 12 are expressed
immune responses to HBs protein were measured in splenic lymphocytes stimulated ex
unstimulated splenocyte cultures. Data are expressed as mean ± standard deviation (n =immunization yielded predominantly IgG1 antibody subclass
(Fig. 2A) and induction of TH2-type cytokines IL-4 and IL-5
(Fig. 2B). There was no change in antibody titers in mice receiving
only the HBs-alum vaccine from weeks 6–12 (data not shown). To
investigate whether NE adjuvant can modify this TH2 bias, the mice
were subsequently immunized with a single intranasal administra-
tion of HBs-NE at 2 or 6 weeks after the second HBs-alum
sensitization (Fig. 1). Serum IgG analysis showed significant
increases in IgG2a and IgG2b subclasses following HBs-NE
immunization, with antibody titers comparable to the HBs-NE
immunization in mice that did not receive the HBs-alum vaccine
(Fig. 2A). Antigen-specific cytokine expression in splenic
lymphocytes after the 6 week NE immunization showed significant
induction of TH1-type IFN-c and TNF-a and the TH17 cytokine IL-17
(Fig. 2B) and decreased IL-4 and IL-5 production in mice
immunized with HBs-NE six weeks after HBs-alum sensitization.Bs-alum to induce TH2 immunity. Mice were subsequently immunized i.n. with HBs-
as ratios of the endpoint titer of each subclass with total IgG titer. (B) Cellular recall
vivo with 5 lg/ml HBs for 48 h. Cytokine secretion has been normalized to control
5). Statistically significant differences (p < 0.05) are indicated by ⁄.
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an earlier time point (2 weeks). Nasal immunization with HBs-NE
alone was used as a control to assess modulation of established
TH2 immunity with NE adjuvant, and antibody and cytokine pat-
terns were similar after HBs-NE immunization regardless of
whether the mice had been previously TH2 sensitized or not
(Fig. 2A and B). There was a slight decrease in IFN-c and IL-17 in
mice that received both vaccines compared with mice immunized
with NE only, however these differences were not statistically sig-
nificant (p = 0.70 and 0.41, respectively).
To investigate a potential role of regulatory T cells (Tregs) in the
mechanism of NE adjuvant, mice were immunized i.n. with ova-NE
or with non-adjuvanted ova in PBS (ova-PBS) as a control. Treg fre-
quency (CD4+ Foxp3+) was measured after 6 days both in the nasal
draining lymph nodes (cervical lymph nodes, cLN) and in the
periphery in splenic lymphocytes. Analysis of CD4+Foxp3+ T cells
showed that mucosal administration of ova-NE induced signifi-
cantly more Treg expansion in both cLN and spleen compared to
ova-PBS and PBS administration (p < 0.03) (Fig. 3A). Interestingly,
by 6 weeks after immunization the frequency of Tregs was ele-
vated in both ova-NE and ova-PBS groups (Fig. 3B). Consistent with
results documented previously, the i.n. immunization with ova-NE
induced a potent IgG response, while no significant titers were
detected in ova-PBS immunized mice (Fig. 3C).
Further analysis revealed that production of IL-10, a suppressive
cytokine associated with Treg function [27,28], was increased in
cells frommice immunized with i.n. ova-NE (Fig. 4A). Furthermore,
IL-10 production was only significantly induced with stimulation
with ova protein or a MHC II-restricted ova peptide, not a MHC I
ova peptide, suggesting that the IL-10 is produced by CD4+ T cells.
Correlates of Treg frequency vs. IL-10 expression show no IL-10
production in mice immunized with ova-PBS despite the increase
in frequency of Treg frequency. In contrast, in mice treated with
ova-NE there was a significant increase in IL-10 levels that closely
correlated with increased Treg frequency (Fig. 4B).Fig. 3. Nasal immunization with NE adjuvant increases frequency of CD4+FoxP3+ regulat
and cervical lymph node cells (cLN) were isolated from the mice and stained with CD4, C
IgG induction was determined at day 42. Statistically significant differences (p < 0.05) aIn order to determine the effects of IL-10 on NE-mediated sup-
pression of the alum-induced TH2 immune response, mice were
immunized i.m. with HBs-alum and IL-10 was depleted at the time
of HBs-NE immunization. There was no balancing of IgG subclasses
when IL-10 was depleted during NE immunization (Fig 5A), and
the subclass pattern was similar to that observed from mice only
receiving the HBs-alum vaccine. The suppression of TH2 cytokines
(IL-4, IL-5, IL-13) did not occur upon HBs-NE immunization with
simultaneous IL-10 depletion. The induction of the TH1 cytokine,
IFN-c, was not inhibited by IL-10 depletion. IL-10 depletion did
not significantly change the percentage of Tregs induced by NE
immunization.
4. Discussion
The development of new materials and adjuvants that can
modulate the immune system is an emerging field in immunology,
with interests in multiple settings, including vaccine development
and allergy [13,29–31]. In this proof of concept study we
present a new adjuvant-based approach to immunomodulation
in mice. We have demonstrated that immunization with novel
oil-in-water nanoemulsion adjuvant not only produced robust
cellular and humoral immunity but also redirected existing
TH2-biased responses towards a more balanced TH1/TH2 phenotype
in a model of established antigen-specific TH2 immunity.
In contrast to the commonly used aluminum adjuvant(s), NE is
not associated with the TH2 phenotype. Consistent with our previ-
ous results [16–18], immunization with NE adjuvant produced TH1
biased immunity with IFN-c and TNF-a production (Fig. 2B). The
significant increase of IgG2a and IgG2b antibodies and TH1 type
cytokines and simultaneous reduction of IgG1 antibodies and TH2
cytokines demonstrates that NE adjuvant is capable of shifting an
established TH2 response towards a more balanced cell-mediated
immunity both through the induction of TH1 and suppression of
TH2. In mice, IgG1 is regulated via a TH2/IL-4 pathway, and inory T cells. Mice were immunized i.n. with ova-NE (n = 4) or ova-PBS (n = 3). Splenic
D25 and Foxp3 at (A) 6 and (B) 42 days after immunization. (C) Serum ova-specific
re indicated by ⁄.
Fig. 4. Correlation of Treg frequency and antigen specific IL-10 expression. Mice
(n = 5) were immunized i.n. with ova-NE or ova-PBS. 42 days after immunization,
splenocytes were harvested and stimulated with ova, or ova-I or ova-II peptides for
48 h. (A) IL-10 secretion in cell culture determined by Milliplex. (B) Splenic Treg
frequency and production of IL-10 after stimulation with ova were plotted for each
individual mouse to demonstrate the correlation between Tregs and IL-10
expression for NE immunized mice.
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for the assessment of a TH2 response [32,33]. Mucosal HBs-NE
immunization of HBs-alum sensitized mice diminished IgG1/IgG2a
and IgG1/IgG2b ratios from 10.46 and 8.67, to 1.2 and 2.1, respec-
tively, clearly demonstrating modulation of the HBs-specific
immune response.
Analysis of cytokine expression provided direct assessment of T
cell activation. Elevated IFN-c and diminished IL-4 levels after anti-
gen stimulation of splenic lymphocytes indicated that HBs-NE
immunization resulted in TH2 cell suppression and a shift to TH1
response (Figs. 2B and 3B). This effect was not detected in spleno-
cytes from mice immunized with NE at an earlier time point
(2 weeks), despite increase in IgG2a and IgG2b antibodies in com-
parison to HBs-alum controls (Fig. 2). This result indicates that
while NE has the potential to modify established TH2 immunity,
effective modification of an ongoing immune response may
depend on the schedule and number of immunizations.
Intranasal immunization with NE adjuvant induces a TH17
immune response [23]. The antigen-specific IL-17 expression was
also detected in splenocytes of mice with TH1 redirected immune
response (Fig. 2B). Despite association with various autoimmune
disorders, TH17 also contributes to host defense as a T cell subset
involved in protection against extracellular pathogens [34] and
has been shown to play a critical role in the efficacy of several vac-
cines [35–39]. Although excessive prolonged IL-17 production may
contribute to pathophysiology of respiratory infections or asthma
and allergy, the degree of TH17 induction with NE immunization
is much lower than levels typically observed in diseases in which
IL-17 contributes to pathology [40,41]. The effect of NE-induced
IL-17 production on TH2/TH1 immunomodulation remains to be
investigated; however, TH17 cell-mediated immunity maysuppress IgE responses, as has been recently indicated for TH17
immunity associated with human autoimmune disease [42].
The exact mechanism of action of NE adjuvant is not yet fully
elucidated. NE is formulated using ultrapure and endotoxin-free
components and does not contain any commonly recognized TLR
agonists or ligands [18]. However, our recent results demonstrate
involvement of the TLR pathway in immunogenicity of NE adjuvant
both in vivo and in vitro [24]. NE facilitates antigen uptake and
trafficking into lymphoid tissue while not causing either nasal
irritation or disruption of mucosal epithelial architecture [43,44].
NE-mediated enhancement of antigen internalization and process-
ing by the antigen presenting cells could be important for the opti-
mal antigen presentation to T cells and development of TH1 biased
immunity [45–47]. We have shown that intranasal treatment with
NE adjuvant does not produce significant amounts of IFN-c, TNF-a,
IL-12, IL-4, IL-5, IL-9, IL-13 or inflammatory cytokines such as IL-1b
in the nasal mucosa [43]. Based on the absence of inflammatory
mediators, rhinitis or cellular infiltrates at the high 20% concentra-
tion, NE appears to be non-inflammatory and is generally biocom-
patible with mucosal and pulmonary tissue in mice, rats, guinea
pigs, dogs and humans (not shown and [18,44,48]).
While data from mouse models clearly show that alum drives
TH2 immunity, the evidence for TH2 skewing by alum based vacci-
nes in humans is not entirely clear. A few clinical studies have
shown that alum induces a mixed TH2 and TH1 response, but the
overall effect across various antigens in humans as compared to
mice is poorly defined [49–52]. Additionally, studies assessing
immune polarization induced by alum mainly have been per-
formed in adults. Given that neonatal immune systems are inher-
ently biased towards TH2 [53,54], the immunization of newborns
with an alum-based Hepatitis B vaccine raises concerns about
the role vaccines might play in the growing issue of allergic disease
in young people [55,56]. Moving forward, it may be advantageous
to consider vaccine adjuvants that induce required protective
immunity without activating TH2 polarized responses. While the
ability of NE adjuvant to shift towards TH1 in humans is not
explored in this study, in a Phase I clinical trial a flu vaccine
containing this NE adjuvant formulation induced TH1 antigen-
specific IgG, neutralizing antibody, as well as mucosal IgA, demon-
strating the immunogenicity of this adjuvant in humans [44].
Here, we demonstrate that NE immunization resulted in the
induction of Tregs in both the draining lymph nodes and the
periphery. The correlating increase in IL-10, suggests that these
Tregs may have suppressive function, and likely play a role in the
immune responses induced by NE [57]. Tregs are considered essen-
tial for the maintenance of immunological homeostasis and for the
control of exacerbated immune responses. Numerous studies have
demonstrated a role for Tregs in restraining exacerbated immune
responses during natural infection, suggesting that Treg depletion
and/or inactivation could improve efficacy of vaccines [58,59].
Much less is known regarding the role of Tregs in the induction
and maintenance of protective immune response with various
adjuvant-based vaccines; however the data presented here suggest
that for NE the induction of Tregs does not inhibit overall vaccine
efficacy but may be responsible for the suppression of the TH2
response. It has previously been reported that antigen-specific
TH1 and regulatory T cells can mediate modification of IgG subclass
pattern [60], consistent with the data presented here. Since Tregs
induced with antigen alone are often considered as immune sup-
pressors in the process of immune tolerance, our results may sug-
gest a functional difference between the Treg populations in mice
immunized with antigen alone compared with antigen and NE.
Similarly, these results may suggest a functional difference
between Treg populations generated in various modes of i.n.
immunization. Further characterization of Treg function and direct
Fig. 5. Suppression of TH2 immunity by NE adjuvant requires IL-10. (A and B) Mice (n = 5) were immunized i.m. with HBs-alum at weeks 0 and 1 followed by i.n. HBs-NE at
week 7. Anti-IL-10 antibodies or rabbit IgG control were administered at the time of NE immunization. (A) Serum HBs-specific antibody subclass titers determined at week 12
are expressed as ratios of the endpoint titer of each subclass with total IgG titer. (B) Cellular recall immune responses to HBs protein were measured in splenic lymphocytes
stimulated ex vivo with 5 lg/ml HBs for 48 h. Cytokine secretion has been normalized to control unstimulated splenocyte cultures. Data are expressed as mean ± standard
deviation. (C) Mice were immunized i.n. with ova-NE or ova-PBS. Cells from cLN were isolated from the mice and stained with CD4, CD25 and Foxp3 at 6 days to measure Treg
frequency.
4022 A.U. Bielinska et al. / Vaccine 34 (2016) 4017–4024functional assessment of their suppressive potential will help to
clarify their role in NE induced immune response.
IL-10 production is one mechanism by which immune
responses can be suppressed. Not only does NE induce IL-10, but
depletion of IL-10 during NE immunization alters the ability of
NE to suppress TH2 immunity (Fig. 5). Interestingly, IL-10 depletion
did not alter TH1 induction by NE, so IL-10 does not appear to be
involved in the induction of immune responses by NE. IL-10 was
depleted during immunization but not at the time of sacrifice
when the recall response to antigen was determined, suggestingthat IL-10 is critical for priming of cellular immune responses that
result in a shift from TH2 to TH1 in this model.5. Conclusions
Our initial results suggest the usefulness of NE-based delivery
systems in the development of therapeutic vaccines to modify
TH2 immune responses, as well as the ability of NE-based vaccines
to retain their immune phenotype even in individuals that received
A.U. Bielinska et al. / Vaccine 34 (2016) 4017–4024 4023previous vaccinations with the same antigen and other adjuvants.
This novel approach to immunomodulation using i.n. delivery of
NE adjuvant to produce mucosal immunity and a systemic
TH1-biased immune response could be useful for the development
of vaccines to induce antigen-specific TH1 immune responses even
in individuals with pre-existing TH2 biased immunity. This sug-
gests that NE adjuvant may be especially useful in situations where
pathologies are due to aberrant TH2 immune response, such as
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